On May 23, 2024 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting (Press release, G1 Therapeutics, MAY 23, 2024, View Source [SID1234643595]). ASCO (Free ASCO Whitepaper) will be held May 31 to June 4, 2024, in Chicago, IL. A copy of the poster will be made available on the G1 Therapeutics website following the presentation here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract was made available by ASCO (Free ASCO Whitepaper) today and includes the initial Phase 2 trial results originally provided by the Company in January 2024. The poster that will be presented at ASCO (Free ASCO Whitepaper) will describe the mature results of the Phase 2 trial as an update to the initial results.

Poster Presentation Details:
Trilaciclib Combined with Sacituzumab Govitecan (SG) in Metastatic Triple Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy Results
Seneviratne, L. et al.
Poster and abstract number 1091
Poster session: Breast Cancer-Metastatic
Sunday, June 2, 2024. 9:00 AM-12:00 PM CDT